Researchers

Mayland Chang, Ph.D.

Mayland Chang, Ph.D.

Assistant Director, Walther Cancer Research Center
Professional Specialist, Department of Chemistry and Biochemistry

Contact Information

  • Office: 163 Stepan Hall
  • Email: mchang@nd.edu
  • Phone: 574-631-2965

Biography

Dr. Chang obtained her B.S. degrees in biological sciences and chemistry in 1980 and 1981, respectively, from the University of Southern California. She received her Ph.D. in chemistry in 1986 from the University of Chicago. Subsequently, she conducted postdoctoral research at Columbia University from 1986 to 1988 as a National Institutes of Health postdoctoral fellow. She joined the faculty of the University of Notre Dame in 2003. Prior to joining the Walther Cancer Research Center, Dr. Chang was Chief Operating Officer of University Research Network, Inc., where she established an academic research organization for Wayne State University School of Medicine that facilitated clinical research and provided clinical development services to the pharmaceutical and biotechnology industries. Previously, Dr. Chang was Senior Scientist with Pharmacia Corporation in Kalamazoo, MI, where her research interests focused on drug metabolism in support of drug discovery and development. Dr. Chang was also Senior Chemist at Dow Chemical Company in Midland, MI, and worked on the development and registration of Broadstrike™ herbicide and Tracer™ insecticide.

Research Interests

Dr. Chang's research interests center on defining the absorption, distribution, metabolism, and excretion of pharmacologically active compounds. In particular, she is interested in improving the pharmacokinetic properties of SB-3CT, the first prototype mechanism-based inhibitor for matrix metalloproteinases. In a collaborative project with Prof. Mobashery, several analogs of this type of inhibitor have been developed with improved selectivity, better aqueous solubility, and more favorable pharmacokinetic properties. The goal is to generate a selective gelatinase inhibitor(s) that will be suitable for preclinical development and eventually advance to clinical trials.

Publications

Krüger A, Arlt MJE, Gerg M, Kopitz C, Bernardo MM, Chang M, Mobashery S, Fridman R, Antimetastatic activity of a novel mechanism-based gelatinase inhibitor. Cancer Res 2005; 65: 4523-3526. link

Ikejiri M, Bernardo MM, Meroueh SO, Brown SB, Chang M, Fridman R, Mobashery S. Design, synthesis and evaluation of a mechanism-based inhibitor for gelatinase A. J Org Chem 2005; 70: 5709-5712. link

Ikejiri M, Bernardo MM, Bonfil RD, Toth M, Chang M, Fridman R, Mobashery S. Potent mechanism-based inhibitors for matrix metalloproteinases. J Biol Chem 2005; 280: 33992-34002. link

Bonfil RD, Sabbota A, Nabha S, Dong Z, Meng H, Yamamoto H, Chinni SR, Berardo MM, Lim I. T, Chang M, Filletti LC, Mobashery S, Cher ML, Fridman, R. Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based selective gelatinase inhibitor. Int J Cancer 2006; 118: 2721-2726. link

Celenza G, Villegas-Estrada A, Lee M, Boggess B, Forbes C, Wolter WR, Suckow MA, Mobashery S, Chang M. Metabolism of (4-phenoxyphenylsulfonyl)methylthiirane, a selective gelatinase inhibitor. Chem Biol Drug Design 2008; 71: 187-196.

Kim DH, Lilliehook C, Roides B, Chen Z, Chang M, Mobashery S, Goldman SA. Testosterone-induced MMP-activation is a checkpoint for neuronal addition to the adult songbird brain. J Neurosc 2008; 28: 208-216. link

Lee M, Villegas-Estrada A, Celenza G, Boggess B, Toth M, Kreitinger G, Forbes C, Fridman R, Mobashery S, Chang M. Metabolism of a highly selective gelatinase inhibitor generates active metabolite. Chem Biol Drug Design 2007; 70: 371-382.

Chang M, Mobashery S. Academic laboratory as a small pharmaceutical company. Medchem News (Japan) 2006; 16: 8-12.

Cells